$LBIO to Participate in Upcoming Investor Conferences


Lion Biotechnologies to Participate in Upcoming Investor Conferences

Lion Biotechnologies, Inc. (LBIO) today announced that president and CEO Elma Hawkins, PhD, will participate in the following upcoming investor conferences:
Piper Jaffray GenomeRx Symposium
Date: Wednesday — Thursday, May 20-21, 2015
Panels: CAR-T: Engineering Lethal Lymphocytes, May 20, 10:25 am; Cellular Therapies: Toolkits and Platforms, May 20, 11:50 am
Location: The New York Palace Hotel, New York
Sachs Immuno-Oncology BD&L and Investment Forum
Date: Friday, May 29, 2015
Panel: Immunotherapeutics: ADCs and Combination Therapies — BD&L, May 29, 10:20 am
Corporate Presentation: May 29, 1:30 pm
Location: Hyatt Chicago Magnificent Mile, Chicago
Jefferies 2015 Healthcare Conference
Date: Monday — Thursday, June 1-4, 2015
Corporate Presentation: June 1, 10:00 am
Location: Grand Hyatt, New York

About Lion Biotechnologies

Lion Biotechnologies, Inc. is engaged in the development of T cells and engineered T cells for the treatment of various cancers. The company’s lead product candidate is a ready-to-infuse, autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with Stage 4 metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and the H. Lee Moffitt Cancer Center & Research Institute. For more information, please visithttp://www.lionbio.com.

Forward Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company’s most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations
The Trout Group
Elizabeth Broder
[email protected]


Please enter your comment!
Please enter your name here